The total transaction size is pegged at around ₹825 crore, according to multiple people familiar with the development.
The floor price for the deal has been set at ₹4,850 per share, which represents a discount of approximately 3% to Alkem’s current market price, sources in the know told CNBC-TV18. Axis Capital is acting as the broker for the transaction, sources close to the development said.
Also Read: Alkem Labs US arm hit by cyber fraud; financial loss under probeQ4
Alkem Laboratories reported a 4.26% year-on-year rise in net profit at ₹306 crore for Q4FY25, falling short of the CNBC-TV18 poll estimate of ₹400 crore. Revenue for the quarter rose 7.1% YoY to ₹3,144 crore, slightly below the poll forecast of ₹3,149 crore.
EBITDA came in at ₹391.5 crore, down 2.6% from ₹402 crore a year ago, and significantly below the expected ₹499 crore. The operating margin stood at 12.45%, lower than 13.69% in the same period last year and well below the street estimate of 16%.
In the Indian market, Alkem registered 6.5% YoY growth in Q4, slightly trailing the broader Indian Pharmaceutical Market’s 6.9%. However, its acute segment outpaced the market, growing 7.5%, or 150 basis points ahead of the IPM.
Also Read: Alkem Labs Q3 Results: Profit and margin expand from last year; dividend announced
Shares of Alkem Laboratories Ltd ended at ₹4,989.00, down by ₹109.50, or 2.15%, on the BSE.
